KemPharm, Inc. (KMPH)
Stock Price:
$0.206 USD
0.000 (0.00%)
Updated May 20, 4:00 PM EDT - Market closed
Key Info
| Market Cap |
14.94M |
| Revenue (ttm) |
12.30M |
| Net Income (ttm) |
-13.94M |
| Shares Out |
70.81M |
| EPS (ttm) |
-0.26 |
| PE Ratio |
n/a |
| Forward PE |
2.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
May 20 |
| Last Price |
$0.206 |
| Previous Close |
$0.206 |
| Change ($) |
0.000 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
0.206 - 0.000 |
| Day's Volume |
0 |
| 52-Week Range |
0.000 - 0.000 |
More Stats
| Market Cap |
14.94M |
| Enterprise Value |
78.18M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
70.81M |
| Float |
n/a |
| EPS (basic) |
-0.33 |
| EPS (diluted) |
-0.26 |
| FCF / Share |
-0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
635,833 |
| Short Ratio |
0.41 |
| Short % of Float |
n/a |
| Beta |
2.69 |
| PE Ratio |
n/a |
| Forward PE |
2.97 |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.22 |
| PB Ratio |
n/a |
| Revenue |
12.30M |
| Operating Income |
-6.81M |
| Net Income |
-13.94M |
| Free Cash Flow |
-3.99M |
| Net Cash |
-63.24M |
| Net Cash / Share |
-0.87 |
| Gross Margin |
80.45% |
| Operating Margin |
-55.33% |
| Profit Margin |
-113.40% |
| FCF Margin |
-32.44% |
| ROA |
-31.00% |
| ROE |
n/a |
| ROIC |
-40.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.50
Current: $0.206
High
1.50
Target: 1.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 12.84 | - | - | - | - | - | - |
| Gross Profit | 12.84 | - | - | - | - | - | - |
| Operating Income | -20.34 | -55.90 | -33.37 | -37.48 | -22.81 | -16.44 | -4.72 |
| Net Income | -24.52 | -56.47 | -43.39 | -16.52 | -54.66 | -24.46 | -5.23 |
| Shares Outstanding | 29.65 | 17.93 | 14.65 | 14.60 | 7.37 | 2.38 | 2.38 |
| Earnings Per Share | -0.83 | -3.15 | -2.96 | -1.13 | -7.42 | -10.27 | -2.20 |
| Operating Cash Flow | -23.74 | -54.20 | -33.10 | -29.77 | -20.27 | -14.67 | -4.33 |
| Capital Expenditures | -0.03 | -0.02 | -0.18 | -0.64 | -0.14 | -0.05 | -0.03 |
| Free Cash Flow | -23.76 | -54.22 | -33.28 | -30.42 | -20.40 | -14.72 | -4.36 |
| Cash & Equivalents | 3.56 | 22.38 | 43.33 | 68.87 | 51.32 | 10.26 | - |
| Total Debt | 79.53 | 82.05 | 93.48 | 91.98 | 21.97 | 18.95 | - |
| Net Cash / Debt | -75.97 | -59.67 | -50.15 | -23.12 | 29.35 | -8.70 | - |
| Assets | 10.51 | 26.75 | 52.46 | 84.89 | 54.59 | 13.71 | - |
| Liabilities | 84.96 | 93.31 | 110 | 104 | 64.71 | 38.02 | - |
| Book Value | -74.46 | -66.57 | -57.52 | -18.70 | -10.12 | -48.51 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
KemPharm, Inc. |
| Country |
United States |
| Employees |
22 |
| CEO |
Travis Mickle |
Stock Information
| Ticker Symbol |
KMPH |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: KMPH |
| IPO Date |
April 16, 2015 |
Description
KemPharm, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.